PharmaCyte Biotech, Inc. PMCB
0.38 USD -0.01 (-1.52%)
At closeNov 5, 2026, 6:30 PM EST
0.36 -0.01 -3.65%
After hours · Nov 5, 6:30 PM ET
0.335 Day range 0.4029
0.3021 52-week range 1.51
- YTD
- -48.18%
- 1 year
- -57.62%
News
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers Onconetix (NASDAQ:ONCO) stock increased by 10.3% to $1.14 during Friday's after-market session. The market value of their outstanding shares is at $3.9 million. Bullfrog AI Hldgs…
benzinga.com PharmaCyte Biotech Q1 EPS $(0.54) Up From $(1.23) YoY, Sales $0.00, Same YoY PharmaCyte Biotech (NASDAQ:PMCB) reported quarterly losses of $(0.54) per share. This is a 56.1 percent increase over losses of $(1.23) per share from the same period last year. The company reported…
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session 
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session 
defenseworld.net Nuvilex (NASDAQ:PMCB) Trading 5.3% Higher – Here’s Why Nuvilex Inc. (NASDAQ: PMCB - Get Free Report) shares traded up 5.3% on Monday. The stock traded as high as $0.6949 and last traded at $0.6879. 85,294 shares were traded during trading, a decline of…- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com PharmaCyte Biotech Receives Noncompliance Notice From Nasdaq; Has Until June 2026 To Regain Compliance On December 1, 2025, PharmaCyte Biotech, Inc. (the "Company") received a written notice (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") indicating…
defenseworld.net Comparing Nuvilex (NASDAQ:PMCB) & Avadel Pharmaceuticals (NASDAQ:AVDL) Avadel Pharmaceuticals (NASDAQ: AVDL - Get Free Report) and Nuvilex (NASDAQ: PMCB - Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies…- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com Why Autodesk Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket - benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session 
benzinga.com PharmaCyte Biotech Monetizes Femasys Stake; Cash And Securities Expected At ~$20M After Monetization, Up From $13.3M PharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the "Company"), today announced the successful monetization of its stake in Femasys Inc. (NASDAQ:FEMY), further validating the Company's…
businesswire.com PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”), today announced the successful monetization of its stake in Femasys Inc. (NASDAQ: FEMY), further…- benzinga.com PharmaCyte Biotech Q1 EPS $(1.23) Down From $1.90 YoY PharmaCyte Biotech (NASDAQ:PMCB) reported quarterly losses of $(1.23) per share. This is a 164.74 percent decrease over earnings of $1.90 per share from the same period last year.
- benzinga.com PharmaCyte Biotech Invests Additional $3M In TNF Pharmaceuticals To Support LightSolver Partnership TNF new strategic partner LightSolver named a 2025 World Economic Forum Technology Pioneer and recognized in Gartner's 2025 Hype Cycle for Data Center Infrastructure TechnologiesPharmaCyte Biotech,…
businesswire.com PharmaCyte Biotech, Inc. Announces Closing of $7 Million Financing LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”), today announced the closing of its previously announced $7 million financing. As of April 30, 2025,…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session 
businesswire.com PharmaCyte Biotech, Inc. Announces $7 Million Capital Raise Led by Existing Investors LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”) announced today that it has entered into a securities purchase agreement for a $7.0 million…
benzinga.com PharmaCyte Biotech Q4 EPS $1.54 Up From $(0.33) YoY PharmaCyte Biotech (NASDAQ:PMCB) reported quarterly earnings of $1.54 per share. This is a 566.67 percent increase over losses of $(0.33) per share from the same period last year.- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga.com PharmaCyte Biotech Makes $7M Investment In MyMD Pharmaceuticals; Investment In Life Sciences Solidifies Previously Announced Strategy To Utilize Significant Cash Position To Create Additional Stockholder Value Second external investment in life sciences solidifies previously announced strategy to utilize significant cash position to create additional stockholder valuePharmaCyte Biotech, Inc. (NASDAQ:PMCB)…
businesswire.com MyMD Pharmaceuticals Secures Strategic Investments BALTIMORE--(BUSINESS WIRE)---- $MYMD--MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for…
businesswire.com PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”), today announced a $7 million investment in MyMD Pharmaceuticals, Inc. (Nasdaq:MYMD) (“MyMD”) a…- benzinga.com PharmaCyte Biotech Acquires $5M Stake In Emerging Women's Health Innovator Femasys, Inc. New investment marks expansion of corporate strategy to utilize significant cash position to create additional shareholder valuePharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the "Company")…
businesswire.com PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women's Health Innovator Femasys, Inc. LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”) announces it has made a $5 million investment in Femasys, Inc. (Nasdaq:FEMY) (“Femasys”), a…- benzinga.com PharmaCyte Biotech Provides Corporate Update On Cell-In-A-Box Technology Company prepares for comprehensive discussion with FDA to determine appropriate next steps for technology while evaluating additional opportunitiesPharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte"…
businesswire.com PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”) provides an update on its investigation of its Cell-in-a-Box technology and initial next steps in…- businesswire.com PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”) provides an update on its investigation of its Cell-in-a-Box technology and initial next steps in…
benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 369 companies set new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 386 stocks made new 52-week lows.
businesswire.com PharmaCyte Biotech Announces Final Results of Tender Offer LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”) today announces the final results of its previously announced tender offer to acquire up to…- benzinga.com Pancreatic Cancer Action Network Urges Advocates From All 50 States To Call On Congress To Increase Federal Funding For Pancreatic Cancer Research Federal Funding Increases Fuel Research Progress and Help Improve Patient OutcomesLOS ANGELES, June 14, 2023 /PRNewswire/ -- The Pancreatic Cancer Action Network (PanCAN), a leading pancreatic cancer…
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- benzinga.com PharmaCyte Biotech Announces Cash Tender Offer For Up To 7.75M Shares At $3.25 Per Share Concurrently, the Company Announces $35 Million Financing of Convertible Preferred Stock at $4.00 per Share PharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the
businesswire.com PharmaCyte Biotech Announces Cash Tender Offer for up to 7,750,000 Shares at $3.25 Per Share LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”) today announces a cash tender offer for up to 7,750,000 shares at $3.25 per share, less any…
businesswire.com PharmaCyte Biotech Announces Cash Tender Offer for up to 7,750,000 Shares at $3.25 Per Share LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”) today announces a cash tender offer for up to 7,750,000 shares at $3.25 per share, less any…
businesswire.com PharmaCyte Biotech to Implement Second $10-Million Share Repurchase Plan LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”), a biotechnology company focused on evaluating its signature live-cell encapsulation technology,…- businesswire.com PharmaCyte Biotech to Implement Second $10-Million Share Repurchase Plan LAS VEGAS--( BUSINESS WIRE )--PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”), a biotechnology company focused on evaluating its signature live-cell encapsulation technology,…
- benzinga.com PharmaCyte Biotech Board Of Directors Announces Business Review Committee To Evaluate Opportunities To Optimize Shareholder Value; CEO Kenneth L. Waggoner Has Stepped Down From The Position As CEO Effective October 6, Joshua N. Silverman As Interim CEO LAS VEGAS, Oct. 07, 2022 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the "Company"), a biotechnology company focused on evaluating its signature live-cell encapsulation
globenewswire.com PharmaCyte Biotech Board of Directors Announces Business Review Committee to Evaluate Opportunities to Optimize Shareholder Value Topics to Include Continued Analysis of FDA's Clinical Hold on IND for Cell-in-a-Box® Topics to Include Continued Analysis of FDA's Clinical Hold on IND for Cell-in-a-Box®
businesswire.com PharmaCyte Biotech Reaches Cooperation Agreement with Iroquois Capital LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes and malignant ascites using its signature…- businesswire.com PharmaCyte Biotech Reaches Cooperation Agreement with Iroquois Capital LAS VEGAS--(BUSINESS WIRE)--PharmaCyte and Iroquois have reached a settlement which includes appointing five new independent directors to PharmaCyte's reconstituted Board.